Adjusted Financial Ratios (Summary)
Adjusted Total Asset Turnover
Adjusted Current Ratio
Adjusted Debt to Equity
Adjusted Debt to Capital
Adjusted Financial Leverage
Adjusted Net Profit Margin
Adjusted Return on Equity (ROE)
Adjusted Return on Assets (ROA)

Regeneron Pharmaceuticals Inc., adjusted financial ratios

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Activity Ratio
Total Asset Turnover
Reported	0.38	0.40	0.42	0.63	0.50
Adjusted	0.42	0.43	0.44	0.65	0.53
Liquidity Ratio
Current Ratio
Reported	4.73	5.69	5.06	3.56	3.63
Adjusted	5.63	6.57	5.96	4.02	4.61
Solvency Ratios
Debt to Equity
Reported	0.09	0.10	0.12	0.14	0.24
Adjusted	0.11	0.12	0.13	0.15	0.25
Debt to Capital
Reported	0.08	0.09	0.11	0.13	0.20
Adjusted	0.10	0.10	0.11	0.13	0.20
Financial Leverage
Reported	1.29	1.27	1.29	1.36	1.56
Adjusted	1.28	1.27	1.28	1.33	1.49
Profitability Ratios
Net Profit Margin
Reported	31.07%	30.14%	35.64%	50.25%	41.35%
Adjusted	27.42%	25.17%	27.95%	48.60%	43.32%
Return on Equity (ROE)
Reported	15.03%	15.22%	19.14%	43.03%	31.86%
Adjusted	14.73%	13.81%	15.88%	42.12%	34.23%
Return on Assets (ROA)
Reported	11.69%	11.95%	14.85%	31.75%	20.47%
Adjusted	11.49%	10.86%	12.41%	31.57%	22.97%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Financial ratio	Description	The company
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Regeneron Pharmaceuticals Inc. adjusted total asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024.
Adjusted current ratio	A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities.	Regeneron Pharmaceuticals Inc. adjusted current ratio improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.
Adjusted debt-to-equity ratio	A solvency ratio calculated as adjusted total debt divided by adjusted total equity.	Regeneron Pharmaceuticals Inc. adjusted debt-to-equity ratio improved from 2022 to 2023 and from 2023 to 2024.
Adjusted debt-to-capital ratio	A solvency ratio calculated as adjusted total debt divided by adjusted total debt plus adjusted total equity.	Regeneron Pharmaceuticals Inc. adjusted debt-to-capital ratio improved from 2022 to 2023 and from 2023 to 2024.
Adjusted financial leverage	A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity. Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.	Regeneron Pharmaceuticals Inc. adjusted financial leverage ratio decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by total revenue.	Regeneron Pharmaceuticals Inc. adjusted net profit margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level.
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by adjusted total equity.	Regeneron Pharmaceuticals Inc. adjusted ROE deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by adjusted total assets.	Regeneron Pharmaceuticals Inc. adjusted ROA deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.

Regeneron Pharmaceuticals Inc., Financial Ratios: Reported vs. Adjusted

Download chart

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Revenues	14,202,000)	13,117,200)	12,172,900)	16,071,700)	8,497,100)
Total assets	37,759,400)	33,080,200)	29,214,500)	25,434,800)	17,163,300)
Activity Ratio
Total asset turnover¹	0.38	0.40	0.42	0.63	0.50
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted revenues²	14,429,800)	13,155,100)	12,205,300)	15,951,500)	8,645,200)
Adjusted total assets³	34,445,300)	30,504,800)	27,490,800)	24,557,900)	16,304,400)
Activity Ratio
Adjusted total asset turnover⁴	0.42	0.43	0.44	0.65	0.53

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
Total asset turnover = Revenues ÷ Total assets
= 14,202,000 ÷ 37,759,400 = 0.38

² Adjusted revenues. See details »

³ Adjusted total assets. See details »

⁴ 2024 Calculation
Adjusted total asset turnover = Adjusted revenues ÷ Adjusted total assets
= 14,429,800 ÷ 34,445,300 = 0.42

Download chart

Activity ratio	Description	The company
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Regeneron Pharmaceuticals Inc. adjusted total asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Current assets	18,660,900)	19,479,200)	15,884,100)	14,014,900)	9,779,100)
Current liabilities	3,944,300)	3,423,400)	3,141,300)	3,932,500)	2,697,400)
Liquidity Ratio
Current ratio¹	4.73	5.69	5.06	3.56	3.63
Adjusted
Selected Financial Data (US$ in thousands)
Current assets	18,660,900)	19,479,200)	15,884,100)	14,014,900)	9,779,100)
Adjusted current liabilities²	3,316,600)	2,964,500)	2,663,400)	3,490,500)	2,119,700)
Liquidity Ratio
Adjusted current ratio³	5.63	6.57	5.96	4.02	4.61

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 18,660,900 ÷ 3,944,300 = 4.73

² Adjusted current liabilities. See details »

³ 2024 Calculation
Adjusted current ratio = Current assets ÷ Adjusted current liabilities
= 18,660,900 ÷ 3,316,600 = 5.63

Download chart

Liquidity ratio	Description	The company
Adjusted current ratio	A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities.	Regeneron Pharmaceuticals Inc. adjusted current ratio improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Total debt	2,704,400)	2,702,900)	2,701,400)	2,699,700)	2,695,700)
Stockholders’ equity	29,353,600)	25,973,100)	22,664,000)	18,768,800)	11,025,300)
Solvency Ratio
Debt to equity¹	0.09	0.10	0.12	0.14	0.24
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted total debt²	2,938,800)	2,790,600)	2,769,600)	2,767,900)	2,763,900)
Adjusted stockholders’ equity³	26,852,900)	23,983,300)	21,488,000)	18,407,200)	10,942,100)
Solvency Ratio
Adjusted debt to equity⁴	0.11	0.12	0.13	0.15	0.25

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 2,704,400 ÷ 29,353,600 = 0.09

² Adjusted total debt. See details »

³ Adjusted stockholders’ equity. See details »

⁴ 2024 Calculation
Adjusted debt to equity = Adjusted total debt ÷ Adjusted stockholders’ equity
= 2,938,800 ÷ 26,852,900 = 0.11

Download chart

Solvency ratio	Description	The company
Adjusted debt-to-equity ratio	A solvency ratio calculated as adjusted total debt divided by adjusted total equity.	Regeneron Pharmaceuticals Inc. adjusted debt-to-equity ratio improved from 2022 to 2023 and from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Total debt	2,704,400)	2,702,900)	2,701,400)	2,699,700)	2,695,700)
Total capital	32,058,000)	28,676,000)	25,365,400)	21,468,500)	13,721,000)
Solvency Ratio
Debt to capital¹	0.08	0.09	0.11	0.13	0.20
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted total debt²	2,938,800)	2,790,600)	2,769,600)	2,767,900)	2,763,900)
Adjusted total capital³	29,791,700)	26,773,900)	24,257,600)	21,175,100)	13,706,000)
Solvency Ratio
Adjusted debt to capital⁴	0.10	0.10	0.11	0.13	0.20

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 2,704,400 ÷ 32,058,000 = 0.08

² Adjusted total debt. See details »

³ Adjusted total capital. See details »

⁴ 2024 Calculation
Adjusted debt to capital = Adjusted total debt ÷ Adjusted total capital
= 2,938,800 ÷ 29,791,700 = 0.10

Download chart

Solvency ratio	Description	The company
Adjusted debt-to-capital ratio	A solvency ratio calculated as adjusted total debt divided by adjusted total debt plus adjusted total equity.	Regeneron Pharmaceuticals Inc. adjusted debt-to-capital ratio improved from 2022 to 2023 and from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Total assets	37,759,400)	33,080,200)	29,214,500)	25,434,800)	17,163,300)
Stockholders’ equity	29,353,600)	25,973,100)	22,664,000)	18,768,800)	11,025,300)
Solvency Ratio
Financial leverage¹	1.29	1.27	1.29	1.36	1.56
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted total assets²	34,445,300)	30,504,800)	27,490,800)	24,557,900)	16,304,400)
Adjusted stockholders’ equity³	26,852,900)	23,983,300)	21,488,000)	18,407,200)	10,942,100)
Solvency Ratio
Adjusted financial leverage⁴	1.28	1.27	1.28	1.33	1.49

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 37,759,400 ÷ 29,353,600 = 1.29

² Adjusted total assets. See details »

³ Adjusted stockholders’ equity. See details »

⁴ 2024 Calculation
Adjusted financial leverage = Adjusted total assets ÷ Adjusted stockholders’ equity
= 34,445,300 ÷ 26,852,900 = 1.28

Download chart

Solvency ratio	Description	The company
Adjusted financial leverage	A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity. Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.	Regeneron Pharmaceuticals Inc. adjusted financial leverage ratio decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Net income	4,412,600)	3,953,600)	4,338,400)	8,075,300)	3,513,200)
Revenues	14,202,000)	13,117,200)	12,172,900)	16,071,700)	8,497,100)
Profitability Ratio
Net profit margin¹	31.07%	30.14%	35.64%	50.25%	41.35%
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted net income²	3,956,100)	3,311,600)	3,411,800)	7,752,500)	3,745,100)
Adjusted revenues³	14,429,800)	13,155,100)	12,205,300)	15,951,500)	8,645,200)
Profitability Ratio
Adjusted net profit margin⁴	27.42%	25.17%	27.95%	48.60%	43.32%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
Net profit margin = 100 × Net income ÷ Revenues
= 100 × 4,412,600 ÷ 14,202,000 = 31.07%

² Adjusted net income. See details »

³ Adjusted revenues. See details »

⁴ 2024 Calculation
Adjusted net profit margin = 100 × Adjusted net income ÷ Adjusted revenues
= 100 × 3,956,100 ÷ 14,429,800 = 27.42%

Download chart

Profitability ratio	Description	The company
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by total revenue.	Regeneron Pharmaceuticals Inc. adjusted net profit margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Net income	4,412,600)	3,953,600)	4,338,400)	8,075,300)	3,513,200)
Stockholders’ equity	29,353,600)	25,973,100)	22,664,000)	18,768,800)	11,025,300)
Profitability Ratio
ROE¹	15.03%	15.22%	19.14%	43.03%	31.86%
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted net income²	3,956,100)	3,311,600)	3,411,800)	7,752,500)	3,745,100)
Adjusted stockholders’ equity³	26,852,900)	23,983,300)	21,488,000)	18,407,200)	10,942,100)
Profitability Ratio
Adjusted ROE⁴	14.73%	13.81%	15.88%	42.12%	34.23%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × 4,412,600 ÷ 29,353,600 = 15.03%

² Adjusted net income. See details »

³ Adjusted stockholders’ equity. See details »

⁴ 2024 Calculation
Adjusted ROE = 100 × Adjusted net income ÷ Adjusted stockholders’ equity
= 100 × 3,956,100 ÷ 26,852,900 = 14.73%

Download chart

Profitability ratio	Description	The company
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by adjusted total equity.	Regeneron Pharmaceuticals Inc. adjusted ROE deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Reported
Selected Financial Data (US$ in thousands)
Net income	4,412,600)	3,953,600)	4,338,400)	8,075,300)	3,513,200)
Total assets	37,759,400)	33,080,200)	29,214,500)	25,434,800)	17,163,300)
Profitability Ratio
ROA¹	11.69%	11.95%	14.85%	31.75%	20.47%
Adjusted
Selected Financial Data (US$ in thousands)
Adjusted net income²	3,956,100)	3,311,600)	3,411,800)	7,752,500)	3,745,100)
Adjusted total assets³	34,445,300)	30,504,800)	27,490,800)	24,557,900)	16,304,400)
Profitability Ratio
Adjusted ROA⁴	11.49%	10.86%	12.41%	31.57%	22.97%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ 2024 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × 4,412,600 ÷ 37,759,400 = 11.69%

² Adjusted net income. See details »

³ Adjusted total assets. See details »

⁴ 2024 Calculation
Adjusted ROA = 100 × Adjusted net income ÷ Adjusted total assets
= 100 × 3,956,100 ÷ 34,445,300 = 11.49%

Download chart

Profitability ratio	Description	The company
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by adjusted total assets.	Regeneron Pharmaceuticals Inc. adjusted ROA deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Adjusted Financial Ratios

Adjusted Financial Ratios (Summary)

Regeneron Pharmaceuticals Inc., Financial Ratios: Reported vs. Adjusted

Adjusted Total Asset Turnover

Adjusted Current Ratio

Adjusted Debt to Equity

Adjusted Debt to Capital

Adjusted Financial Leverage

Adjusted Net Profit Margin

Adjusted Return on Equity (ROE)

Adjusted Return on Assets (ROA)